Puma Biotechnology, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited results; comparisons are with Q1 2023 unless noted. Puma develops and commercializes cancer therapies. Its marketed product is NERLYNX (neratinib); it is also developing licensed drug candidate alisertib.
Financial highlights
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $43.8 million | $52.8 million; down 17.1% |
| NERLYNX product revenue, net | $40.3 million | $46.8 million; down 13.9% |
| Royalty revenue | $3.5 million | $6.0 million; down 41.7% |
| Gross profit and gross margin | $33.0 million; 75.5% | $39.6 million; 75.0% |
| Operating income (loss) and margin | $(2.3) million; (5.3)% | $4.4 million; 8.3% |
| Net income (loss) and EPS | $(4.8) million; $(0.10) per share | $1.4 million; $0.03 per share |
| Cash from operations | $11.2 million | $2.6 million |
| Cash, cash equivalents and marketable securities | $107.2 million | At March 31, 2024 |
| Working capital | $44.8 million | Down from $56.8 million at December 31, 2023 |
| Debt | $100.0 million principal; $102.0 million including exit payment | Notes mature July 2026 |
Cash, cash equivalents and restricted cash totaled $78.8 million at quarter-end. Cash and cash equivalents alone were $76.8 million; marketable securities were $30.4 million. Cash, cash equivalents and restricted cash decreased $7.8 million during the quarter as investing outflows, mainly purchases of securities, exceeded operating cash generation. The company reported a $4.8 million net loss despite positive operating cash flow; the cash-flow statement reflects, among other items, lower accounts receivable and reductions in accrued expenses.
SG&A declined 3.3% to $21.8 million, while R&D increased 6.9% to $13.6 million. Interest expense was $3.4 million. Company-presented non-GAAP adjusted net loss, excluding stock-based compensation, was $2.4 million, or $0.05 per share; this measure is not a substitute for GAAP results.
Material changes and business developments
- Product revenue fell primarily as NERLYNX bottles sold declined 15.4% and variable-consideration deductions increased; higher net selling price partly offset the decline.
- Royalty revenue decreased mainly due to the timing of sales by the company’s China sublicensee. Cost of sales fell to $10.7 million, primarily reflecting lower royalty expense alongside lower worldwide sales.
- Operating results shifted from income to loss. Revenue declined by $9.0 million, while total operating costs and expenses decreased by $2.3 million.
- Cash from operations improved year over year, partly reflecting a $23.1 million reduction in accounts receivable; this working-capital movement should not be assumed to recur.
- Puma initiated the ALISCA-Lung1 Phase II trial of alisertib in extensive-stage small cell lung cancer in February 2024 and plans to begin the ALISCA-Breast 1 trial in the second half of 2024.
Outlook, risks and contingencies
- Management believes cash, marketable securities, product sales and sublicense payments will fund operating and capital needs for at least one year after filing. The company cautions that this depends on assumptions and that additional financing may be needed; there is no assurance it can be obtained.
- The Athyrium notes carry a 12.99% effective interest rate as of March 31, 2024, are secured by substantially all company assets, and require quarterly principal payments beginning June 30, 2024. A 100-basis-point increase in interest rates would have increased quarterly interest expense by $1.0 million, according to the filing. The notes include minimum cash and product-revenue covenants and restrictions on financial flexibility. MD&A states the company was in covenant compliance at March 31, 2024.
- The exhibit list identifies a Seventh Amendment to the Athyrium Note Purchase Agreement dated April 12, 2024; the supplied filing text does not explain its terms. The debt note’s covenant-compliance sentence refers to March 31, 2023, while MD&A refers to March 31, 2024.
- Athyrium principal and exit payments total $102.0 million, with scheduled payments of $34.0 million in 2024, $45.3 million in 2025 and $22.7 million in 2026. Separately, $8.0 million remains payable under the Eshelman settlement on or before November 1, 2024.
- NERLYNX faces generic competition risk in China: Acebright received approval to market a generic in September 2023, and Puma’s later patent-infringement case has a hearing scheduled for June 20, 2024. Other Chinese generic applications and patent proceedings are also disclosed.
- In the AstraZeneca patent litigation, Puma was dismissed as a plaintiff on standing grounds, but the company says it retains contractual rights to recover monetary damages under its Pfizer license. Wyeth remains in the case; a jury trial was scheduled to begin May 13, 2024. The legal-malpractice case was dismissed in March 2024 and Puma appealed.
- Takeda may receive up to $287.3 million in future alisertib milestones plus tiered royalties. Sublicense agreements may generate up to approximately $579.8 million in NERLYNX milestone payments, but Puma says timing and achievement cannot currently be estimated.
- Additional risks include reliance on third-party manufacturers, NERLYNX concentration as the company’s principal product, clinical and regulatory uncertainty for alisertib, and potential dilution or operating constraints if further financing is required. No specific financial guidance was provided in the supplied filing text.
Important facts for investors to verify
- Whether NERLYNX sales and international royalties stabilize, and whether the decline in bottles sold and China-related royalty timing persist.
- The terms of the April 12, 2024 Athyrium amendment, the applicable covenant thresholds, and the company’s compliance status; clarify the inconsistent covenant reference to 2023 versus 2024.
- Cash generation and liquidity after scheduled Athyrium principal payments begin, including the $8.0 million Eshelman settlement payment due by November 1, 2024.
- Alisertib trial enrollment, timing, costs and clinical results, including progress toward the planned second-half 2024 breast-cancer trial.
- Developments and potential financial outcomes in the AstraZeneca and China patent matters, including the effect of generic NERLYNX availability in China.
- Whether sublicense milestones and royalties become attainable and provide meaningful cash inflows; the filing does not establish when or whether they will be achieved.